



**ImmunOs Therapeutics AG appoints Sean R. Smith as new Chief Executive Officer and Dr. Osiris Marroquin-Belaunzaran as Chief Scientific Officer**

Schlieren (Zurich Area), Switzerland. – June 6, 2017 –ImmunOs Therapeutics AG, a Swiss bio-technology company leading the next generation of immunotherapies for cancer, today announced the appointment of Sean R. Smith to Chief Executive Officer and the company’s Board of Directors.

Mr. Smith succeeds the current Chief Executive Officer and Co-Founder, Dr. Osiris Marroquin-Belaunzaran who is assuming the position of Chief Scientific Officer and Chairman of the company’s Board of Directors.

Mr. Smith brings deep commercial and cross-departmental leadership experience to ImmunOs Therapeutics AG to support moving our next generation, novel immuno-oncology therapies from pre-clinical development through commercialization. He joins ImmunOs Therapeutics AG after recently spending over 15 years at MSD/Merck and Co., Inc in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, country, and regional operations with broad exposure to multiple therapeutic areas including early-stage clinical, in-line, and launch portfolios in Hospital/Specialty, Infectious Disease, General Medicine, and Vaccines. He has extensive leadership experience in global markets focused in North America, Europe, Asia-Pacific, China, Japan, and Latin America.

Dr. Osiris Marroquin-Belaunzaran said “Sean brings great depth of expertise in global commercial and cross-departmental leadership with a strong ability to inspire and lead our company and team. He will play a pivotal role in building ImmunOs Therapeutics AG into an international leader in discovering and developing the next generation of immuno-oncology targets”.

“Immuno-oncology is well-recognized as a revolutionary breakthrough in how cancer patients are being treated. It will continue to experience significant growth and changes as experts are now recognizing the importance of a next generation of novel therapeutics to advance treatment success for patients. The first-generation of immunomodulators are setting the foundation for the future, but more discovery and development is needed for many of the most difficult to treat cancers” said Mr. Smith. “ImmunOs Therapeutics AG has already made impressive progress in advancing its core programs forward in multiple cancers including Pancreatic, Colon, Melanoma, Breast, and Lymphoma. I am proud to join this exceptional group of founders, board of directors, and the rest of the ImmunOs Therapeutics AG team. I look forward to advancing the company’s next generation, novel programs forward to improve patients’ lives.”

About ImmunOs Therapeutics AG:

ImmunOs Therapeutics AG is a biotechnology company focused on discovering and developing the next generation of novel human immunomodulatory proteins. Our mission is to develop novel therapeutics that will improve the lives of patients with serious diseases.

ImmunOs Therapeutics AG lead program is a next generation, novel target that differs from the common competitor antibodies as they target diverse immunoregulatory receptors using one molecule to create a synergistic response between immune cells that activate anti-tumor responses built upon years of research and development. ImmunOs Proteins work directly on the Innate Immune System (Macrophages and NK Cells) and Indirectly on the Adaptive Immune System by targeting MDSCs and thus allowing the expansion of T cells leading to a strong anti-tumor response in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB) in multiple cancer indications. For more information, please visit [www.immunotherapeutics.com](http://www.immunotherapeutics.com).



Contact:

Investor Relations

Wagistrasse 14

8952 Schlieren (Zurich Area)

[info@immunotherapeutics.com](mailto:info@immunotherapeutics.com)